$1.3 million in NIH grants to enable research into antibody-mediated drug delivery technology

Two National Institute of Health (NIH) grants totaling over $1.3 million will enable research into antibody-mediated drug delivery technology for the treatment of cancer and autoimmune disorders. L. Nathan Tumey, assistant professor of pharmaceutical sciences, is the Principal Investigator on both grants — $1.2 million from the National Institute of General Medical Sciences and $150,000 from the National Institute of Allergy and Infectious Diseases.

NUS researchers develop novel technique to automate production of pharmaceutical compounds

Giving a new spin to conventional chemical synthesis, a team of researchers from the National University of Singapore (NUS) has developed a way to automate the production of small molecules suitable for pharmaceutical use. The method can potentially be used for molecules that are typically produced via manual processes, thereby reducing the manpower required.

Leveraging Modeling and Simulation in Medicine at VisualizeMED

ASME’s VisualizeMED: Modeling and Simulation in Medicine will take place on April 14-15, 2021. This two-day virtual event is enabling the transformation of modeling and simulation in medicine by bringing together industry experts of technology and masters of technique who are effectively implementing it with the goal to increase the application and adoption on a global scale.

Researchers watch anti-cancer drug release from DNA nanostructures in real time

A team of researchers from Finland and Germany have found a way to study the endonuclease-driven digestion of drug-loaded DNA nanostructures in real time. As the team investigated the binding of anti-cancer drug doxorubicin (Dox) to the DNA structures in great detail, they discovered that the majority of previous studies have vastly overestimated the Dox loading capacity of DNA origami.

Case Western Reserve University teams with Boehringer Ingelheim on artificial intelligence solutions for precision medicine

The Center for Computational Imaging and Personalized Diagnostics (CCIPD) at Case Western Reserve University and Boehringer Ingelheim, one of the world’s largest pharmaceutical companies will leverage the power of CCIPD’s image computing AI solutions to identify patterns and links between cellular response and underlying molecular drivers, with the goal of advancing therapeutics for diseases with no satisfactory treatment option.

Optimizing Patient Access to Medications: The American Dermatological Association’s Position Statement on Pharmacy Benefit Managers (PBMs) and Patient Access to Affordable and Appropriate Medications

Access to healthcare has been at the forefront of social and political debate for decades. Reliable and equitable access to provider prescribed medications is tantamount to the delivery of appropriate healthcare, and the lifecycle of medication manufacturing, distribution, pricing and procurement has been shrouded in an incomprehensible array of transactions and involved stakeholders. Among the middlemen interspersed between pharmaceutical manufacturers and patients are pharmacy benefit managers (PBM). Initially tasked with administering drug plans for health insurers,1 the role of PBMs has expanded over time. They currently function in a lightly regulated area,2,3 with few requirements for business transparency. Three PBMs, CVS Caremark, Optum RX, and Express Scripts, control distribution of nearly ¾ of the medications in the United States.

Lab researchers aid COVID-19 response in antibody, anti-viral research

Lawrence Livermore National Laboratory scientists are contributing to the global fight against COVID-19 by combining artificial intelligence/machine learning, bioinformatics and supercomputing to help discover candidates for new antibodies and pharmaceutical drugs to combat the disease.

COVID-19 big picture: For many years, Pinar Keskinocak has studied how society and the nation handle pandemics.

For many years, Pinar Keskinocak has studied how pandemics spread through the nation, how they overburden health care systems, and how they diminish the supply of medications, thus worsening the pandemic. All this also spins off additional medical crises. She…

Coronavirus multiple-times worse than SARS: Global supply-chain effect could exceed $400bn, linger up to 2 years — WashU expert

Panos Kouvelis 314-935-4604 [email protected]   Please read: https://source.wustl.edu/2020/02/washu-expert-coronavirus-far-greater-threat-than-sars-to-global-supply-chain/ Please watch: https://youtu.be/ATzgs67Dnx8   Original post https://alertarticles.info